BCG
UTHR icon

BayBridge Capital Group’s United Therapeutics UTHR Stock Holding History

BayBridge Capital Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,560
Closed -$342K – 98
2023
Q4 		$342K Buy
+1,560
New +$360K 0.32% 75

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BayBridge Capital Group's UTHR Position: Q1 2024 in Review

BayBridge Capital Group sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 1,560 shares — an estimated $342K sold.

BayBridge Capital Group first reported a position in UTHR in Q4 2023 and held it in 1 quarter. The position peaked at $342K in Q4 2023. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

  • BayBridge Capital Group reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
  • BayBridge Capital Group sold 1,560 United Therapeutics shares in Q1 2024, an estimated $342K.
  • BayBridge Capital Group first reported a position in United Therapeutics in Q4 2023 and held it in 1 quarter.
  • BayBridge Capital Group's United Therapeutics position peaked at $342K in Q4 2023.
  • 525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on BayBridge Capital Group's 13F filing for Q1 2024, filed 26 Apr 2024.